At AstraZeneca we are dedicated to redefining the future of healthcare by unlocking the power of what science can do for people, society and the planet. Working here means being bold, thinking big and working together to make the impossible a reality.

Working at AstraZeneca means being entrepreneurial, thinking big, and working together to make the impossible a reality. We are focused on the potential of science to address the unmet needs of patients around the world.

To deliver our medicines to patients we need to submit evidence to HTA bodies around the world, requiring expertise in HTA science where we can translate data into evidence to quantify the benefit of our medicines. And in Europe, the start of the Joint Clinical Assessment (JCA) will require innovative solutions in demonstrating our comparative effectiveness through direct and indirect analyses.

With our expanding oncology portfolio and the start of European JCA, we are looking for a passionate and dedicated individual to join our oncology HTA and Modelling Science (HMS) team who has experience and pragmatic expertise in undertaking indirect comparisons and other evidence synthesis techniques to support our global HTA work. Working collaboratively with our R&D and payer statistics teams, your subject matter expertise will play a central role in helping to secure patient access to our innovative medicines.

Furthermore, as the first disease area the EU HTA Regulation applies to is oncology, you will be at the forefront of gaining early, first-hand experience of applying your expertise to the analytic approach, analyses and interpretation of our joint clinical assessment dossiers.

Typical Accountabilities:

• Contribute to development of strategic approach and delivery of HTA comparative effectiveness analyses for assigned medicines, including use of network meta analyses (NMA), population-adjusted and standard indirect treatment comparisons methods
• Application of novel indirect comparison techniques, surrogacy methods, survival and regression analyses, etc.
• Beyond HTA and market access, identify and apply HTA methods to support wider cross functional decision-making and goals (e.g. medical and commercial)
• Provide leadership, input and support for the development of HTA& Modelling Science guidance documents, internal initiatives, as well as external publications
• Develop the JCA and HTA analysis plans, and input into the strategic and analytic approaches to questions and challenges associated with reimbursement of oncology medicines
• Contribute to quality assurance of the team’s work, projects led by external vendors, global standards, best practice, and metrics
• Build partnerships and working relationships with cross-functional partners
  
  
  

Crucial Skills/Experience:

• Bachelors’ or Masters’ degree in statistics/biostatistics or equivalent quantitative degree with a statistical component
• Prior experience working in consultancy or industry in applying expertise to support HTA submissions
• Understanding and application of statistical principles, methods, and procedures in the HTA setting, including indirect comparison methods, evidence synthesis, clinical trial analysis or analysis of other large datasets
• Statistical expertise in meta-analysis and clinical trial analysis for HTA
• Proficiency in statistical software / programming coding (for example, R, SAS or WinBugs)
• Confirmed oral and written skills in communication of methods, results and data interpretation to different audiences
• Understanding of how HTA science can impact on wider market access and value communication
• Ability to work both independently and as a team
  
  
  

Desirable Skills/Experience:

• Knowledge and experience across different oncology tumour types or disease stage settings
• Experience in contributing to HTA submissions and responding to questions in at least one HTA market
• Knowledge of the role of indirect treatment comparison in cost-effectiveness models
• Statistical analysis and interpretation of patient reported outcomes
• Knowledge of the changing HTA methods requirements globally and how to approach these.
• Familiarity with German IQWiG submissions
  
  
  

Key Partners:

• HTA and Modelling Science colleagues
• Oncology biometrics (statistics and programming)
• Health Economics & Payer Evidence and the wider Oncology Market Access and Pricing (OMAP) community
• Marketing company / local affiliate HTA/HEOR related teams
• Medical affairs and medical evidence teams
• Clinical outcomes assessment team
• Clinical Development teams